



AIFA approves use of the Comirnaty vaccine for the 12-15 years age group

The AIFA Scientific-technical Committee (CTS) has approved the extension of indications of the (BioNTech/Pfizer) Comirnaty vaccine for the age group between 12 and 15 years, fully accepting the opinion issued by the European Medicines Agency (EMA).

According to the CTS, available data show that the vaccine is effective and safe also in subjects included in this age bracket.